Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00472 ...
Drug Name Fluoxetine
Molecular Weight 309.3261
Molecular Formula C17H18F3NO
CAS Number 54910-89-3
SMILES CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
External Links
DRUGBANK DB00472
T3DB T3D2802
PubChem Compound 3386
PDR 1416
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 4.05 - 4.05 - ADLARD,M ET AL. (1995)
Boiling Point 395.1 ℃ 395.1 ℃ https://www.lookchem.com/Fluoxetine/
Melting Point 195.0 ℃ 193-197 ℃ MSDS

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 90.0 % <90 % DRUGBANK
C Max 11.8 ng/ml 11.754 ng/ml DRUGBANK
C Max 365.5 ng/ml 200-531 ng/ml PO, oral; The Pharmacological Basis of Therapeutics
C Max 284.0 ng/ml 103-465 ng/ml PO, oral; The Pharmacological Basis of Therapeutics
T Max 7.0 h 6-8 h PO, oral; The Pharmacological Basis of Therapeutics
Clearance 0.58 L/h/kg 9.6 ml/min/kg normal,healthy; patients; DRUGBANK
Clearance 0.58 L/h/kg 9.6±6.9 ml/min/kg apparent clearance; Drug combination; hydrolysis; Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ;increasing doses ↓ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 31.0 L/kg 20-42 L/kg DRUGBANK
Volume of Distribution 35.0 L/kg 35±21 L/kg Apparent volume of distribution; Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Half-life 48.0 h 1-3 day elimination half-life; DRUGBANK
Half-life 120.0 h 4-6 day elimination half-life; Oral multiple dose; DRUGBANK
Half-life 240.0 h 4-16 day elimination half-life; Oral multiple dose; DRUGBANK
Half-life 53.0 h 53±41 h Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ;increasing doses ↑ ;Age → ; The Pharmacological Basis of Therapeutics
Toxicity LD50 284.0 mg/kg 284.0 mg/kg PO, oral; mouse; T3DB
Eliminate Route 2.5 % <2.5 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 94.0 % ~94 % plasma proteins; DRUGBANK
Protein Binding 94.0 % 94 % Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Frequency Brand Name Component Reference
Max dose for children 60.0 mg/day 60 mg/day PO, oral Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for children 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for children 60.0 mg/day 60 mg/day PO, oral Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for children 0.5 mg/kg/day 0.5 mg/kg/day PO, oral Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for children 40.0 mg/day 40 mg/day PO, oral Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for adolescents 60.0 mg/day 60 mg/day PO, oral Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for adults 80.0 mg/day 80 mg/day PO, oral qd Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for adults 12.8571428571429 mg/day 90 mg/week PO, oral qw Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for geriatric 80.0 mg/day 80 mg/day PO, oral qd Fluoxetine Tablets fluoxetine hydrochloride PDR
Max dose for geriatric 12.8571428571429 mg/day 90 mg/week PO, oral qw Fluoxetine Tablets fluoxetine hydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1